Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Neurophysiological Anomalies in Schizophrenia: Potential Drug Targets or Biomarkers?

Neurophysiological Anomalies in Schizophrenia: Potential Drug Targets or Biomarkers?

Tuesday, January 24, 2006

The New York Academy of Sciences

Organizers: Mihaly Hajos, Pfizer; Clay Scott, AstraZeneca

Abnormal sensory processing is thought to be one of the core pathological mechanisms causal to schizophrenia. Disrupted auditory gating, abnormal P300 evoked potentials, and deficits in mismatch negativity in schizophrenic patients are regarded as markers of this impairment. Recently, abnormalities in event related neuronal synchrony or oscillatory activities have been postulated as the electrophysiological correlates the distorted perception and cognitive dysfunction associated with schizophrenia. Our emerging understanding of these neuronal circuitry dynamics could reveal not only the pathophysiology of the disorder, but indicate potential targets for novel antipsychotic drug therapy.



1:00—1:10 Introduction
Mihaly Hajos, Pfizer Global R & D, Groton, Connecticut

Kevin M. Spencer, VA Boston Healthcare System/Harvard Medical School, Brockton, Massachusetts, "Neurophysiological Correlates of Disorderd Perception and Cognition in Schizophrenia."

Georg Winterer, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, "Impaired Neuronal Processing of Frontal Cortical Regions in Schizophrenic Patients."

3:00—3:20 Coffee Break

Gunvant K. Thaker, Maryland Psychiatric Research Center, Baltimore, Maryland, "Schizophrenia Endophenotypes as Treatment Targets."

Daniel C. Javitt
, MD, PhD, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York; New York University School of Medicine, New York, New York, "Impaired Mismatch Negativity Generation Reflects Dysfunction of Working Memory in Schizophrenia."

5:10—5:20 Questions and Closing Comments
Clay Scott, PhD, AstraZeneca, Wilmington, Delaware